Naredi P - Search Results

1

Expression pattern and circulating levels of endostatin in patients with pancreas cancer.

Ohlund D, Ardnor B, Oman M, Naredi P, Sund M. Ohlund D, et al. Among authors: naredi p. Int J Cancer. 2008 Jun 15;122(12):2805-10. doi: 10.1002/ijc.23468. Int J Cancer. 2008. PMID: 18360823

2

Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.

Oman M, Blind PJ, Naredi P, Gustavsson B, Hafström LO. Oman M, et al. Among authors: naredi p. Eur J Surg Oncol. 2001 Aug;27(5):477-81. doi: 10.1053/ejso.2001.1157. Eur J Surg Oncol. 2001. PMID: 11504519

3

A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases.

Naredi P, Oman M, Blind PJ, Lindnér P, Gustavsson B, Hafström L. Naredi P, et al. Eur J Surg Oncol. 2003 Jun;29(5):459-66. doi: 10.1016/s0748-7983(03)00002-7. Eur J Surg Oncol. 2003. PMID: 12798752 Clinical Trial.

4

Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.

Oman M, Tölli J, Naredi P, Hafström LO. Oman M, et al. Among authors: naredi p. Cancer Chemother Pharmacol. 2004 Sep;54(3):213-8. doi: 10.1007/s00280-004-0812-3. Epub 2004 May 11. Cancer Chemother Pharmacol. 2004. PMID: 15138707

5

Blood flow in liver tumors--effects of vasoactive drugs estimated with xenon (133Xe) clearance.

Lindnér P, Tölli J, Naredi P, Oman M, Hafström L. Lindnér P, et al. Among authors: naredi p. Hepatogastroenterology. 2004 May-Jun;51(57):781-6. Hepatogastroenterology. 2004. PMID: 15143916

6

133Xe clearance estimates the effect of vasopressin on peritoneal blood flow in rats.

Oman M, Tölli J, Blind PJ, Naredi P, Hafström LO. Oman M, et al. Among authors: naredi p. Hepatogastroenterology. 2004 Jul-Aug;51(58):1037-41. Hepatogastroenterology. 2004. PMID: 15239241

7

Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.

Oman M, Lundqvist S, Gustavsson B, Hafström LO, Naredi P. Oman M, et al. Among authors: naredi p. Cancer Chemother Pharmacol. 2005 Dec;56(6):603-9. doi: 10.1007/s00280-005-1012-5. Epub 2005 Jul 27. Cancer Chemother Pharmacol. 2005. PMID: 16047145 Clinical Trial.

8

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer.

Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M. Ohlund D, et al. Among authors: naredi p. Br J Cancer. 2009 Jul 7;101(1):91-7. doi: 10.1038/sj.bjc.6605107. Epub 2009 Jun 2. Br J Cancer. 2009. PMID: 19491897 Free PMC article.

9

Type IV collagen as a tumour marker for colorectal liver metastases.

Nyström H, Naredi P, Hafström L, Sund M. Nyström H, et al. Among authors: naredi p. Eur J Surg Oncol. 2011 Jul;37(7):611-7. doi: 10.1016/j.ejso.2011.04.010. Epub 2011 May 28. Eur J Surg Oncol. 2011. PMID: 21620632

10

Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour.

Nyström H, Naredi P, Berglund A, Palmqvist R, Tavelin B, Sund M. Nyström H, et al. Among authors: naredi p. Anticancer Res. 2012 Dec;32(12):5183-91. Anticancer Res. 2012. PMID: 23225415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters